The prevalence of EML4-ALK variants in patients with non-small-cell lung cancer: a systematic review and meta-analysis

To investigate the prevalence of  variants in non-small-cell lung cancer (NSCLC) patients. Database of Pubmed, Embase, Medline and Cochrane Library were searched systematically to April 2018. A total of 39 articles including 1903 NSCLC patients with positive were recruited. The overall pooled preval...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers in medicine 2019-08, Vol.13 (12), p.1035-1044
Main Authors: He, Yuan, Sun, Li-Yue, Gong, Rui, Liu, Qing, Long, Ya-Kang, Liu, Fang, Wang, Fang
Format: Article
Language:English
Subjects:
Collaboration
Laboratories
Lung cancer
Medicine
Meta-analysis
Non-small cell lung carcinoma
Oncology
Polymerase chain reaction
Small cell lung carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the prevalence of  variants in non-small-cell lung cancer (NSCLC) patients. Database of Pubmed, Embase, Medline and Cochrane Library were searched systematically to April 2018. A total of 39 articles including 1903 NSCLC patients with positive were recruited. The overall pooled prevalence for variant 1 to 3 was 81.84% (95% CI: 76.68-86.99%), ranging from 86.64% tested by RT-PCR to 70.85% tested by other methods (p = 0.00). Subgroup analysis showed that the pooled prevalences of variant 1, 2 and 3 were 40.38% (95% CI: 34.83-45.93%), 6.59% (95% CI: 4.27-8.91%) and 26.54% (95% CI: 20.89-32.2%), respectively. This present study provides the exact prevalence of rearrangement in different variants for NSCLC patients with positive.
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm-2018-0277